Updated Jul 16, 2026 · Last SEC filing 2026-07-07
VERTEX PHARMACEUTICALS INC / MA (VRTX) has filed 25 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-07. 4 Form 8-K material event filings were reported by VRTX in the last 90 days. 15 Form 144 notices of proposed sale were filed for VRTX stock. InsiderAlpha tracks every VRTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0000875320 |
| Form 4 filings (90d) | 25 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 15 |
| Latest Form 4 filing | 2026-07-07 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| McKechnie Duncan | EVP, Chief Commercial Officer | S — Open-market sale | 1.5K | $519.00 | $800K | SEC | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | S — Open-market sale | 1.5K | $524.99 | $787K | SEC | |
| Liu Joy | EVP and Chief Legal Officer | S — Open-market sale | 828 | $502.71 | $416K | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 596 | $482.50 | $288K | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 1.0K | $462.17 | $471K | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 4.1K | $450.00 | $1.83M | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 1.7K | $450.00 | $785K | SEC | |
| Liu Joy | EVP and Chief Legal Officer | S — Open-market sale | 828 | $439.91 | $364K | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 2.0K | $450.00 | $888K | SEC | |
| Bunnage Mark E. | EVP, Chief Scientific Officer | S — Open-market sale | 33 | $453.45 | $15K | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 1.4K | $453.45 | $614K | SEC | |
| Bozic Carmen | EVP and CMO | S — Open-market sale | 7.0K | $450.00 | $3.14M | SEC | |
| Bhatia Sangeeta N. | Director | S — Open-market sale | 318 | $423.73 | $135K | SEC | |
| Liu Joy | EVP and Chief Legal Officer | S — Open-market sale | 1.1K | $425.02 | $469K | SEC | |
| MCKENZIE DIANA | Director | D — Derivative transaction | 796 | — | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for VERTEX PHARMACEUTICALS INC / MA (VRTX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Bozic Carmen | 7 | $8.02M |
| Upadhyay Suketu | 4 | $36K |
| Schneider Jennifer | 4 | — |
| Thornberry Nancy | 4 | — |
| MCKENZIE DIANA | 3 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in VRTX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live VRTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.